Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease

NCT01569516 is registered in ClinicalTrials.gov with Changchun Huayang High-tech Co., Ltd as lead sponsor.

NCT NCT01569516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01569516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease
Lead sponsor
Changchun Huayang High-tech Co., Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2011
Completion date
October 31, 2012
Enrollment
288 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease